- Home
- GXAI vs ADXN Comparison
GXAI vs ADXN Comparison
Compare GXAI & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- ADXN
- Stock Information
- Founded
- GXAI 2021
- ADXN 2002
- Country
- GXAI United States
- ADXN Switzerland
- Employees
- GXAI N/A
- ADXN N/A
- Industry
- GXAI
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- GXAI
- ADXN Health Care
- Exchange
- GXAI Nasdaq
- ADXN Nasdaq
- Market Cap
- GXAI 9.7M
- ADXN 8.1M
- IPO Year
- GXAI 2023
- ADXN N/A
- Fundamental
- Price
- GXAI $1.54
- ADXN $9.38
- Analyst Decision
- GXAI
- ADXN Strong Buy
- Analyst Count
- GXAI 0
- ADXN 1
- Target Price
- GXAI N/A
- ADXN $30.00
- AVG Volume (30 Days)
- GXAI 132.5K
- ADXN 17.4K
- Earning Date
- GXAI 08-12-2025
- ADXN 08-11-2025
- Dividend Yield
- GXAI N/A
- ADXN N/A
- EPS Growth
- GXAI N/A
- ADXN N/A
- EPS
- GXAI N/A
- ADXN 0.10
- Revenue
- GXAI $27,740.00
- ADXN $278,508.00
- Revenue This Year
- GXAI N/A
- ADXN $86.57
- Revenue Next Year
- GXAI N/A
- ADXN N/A
- P/E Ratio
- GXAI N/A
- ADXN $0.76
- Revenue Growth
- GXAI 9987.27
- ADXN N/A
- 52 Week Low
- GXAI $1.00
- ADXN $6.51
- 52 Week High
- GXAI $7.50
- ADXN $13.27
- Technical
- Relative Strength Index (RSI)
- GXAI 61.62
- ADXN 58.19
- Support Level
- GXAI $1.30
- ADXN $8.50
- Resistance Level
- GXAI $1.53
- ADXN $9.87
- Average True Range (ATR)
- GXAI 0.07
- ADXN 0.78
- MACD
- GXAI 0.01
- ADXN 0.05
- Stochastic Oscillator
- GXAI 89.66
- ADXN 72.46
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.